Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of enlicitide decanoate for prevention of major cardiovascular events in high-risk ASCVD
NL-OMON60289Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2024
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and hypercholesterolemia comparing Enlicitide decanoate with Placebo (2 arms). Primary endpoint: Time to first occurrence of CHD death-based MACE-plus. Started Jun 2024; status: active, not recruiting.
02
Drugs
enlicitide
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on NL-OMON60289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60289.